Smoking Cessation Treatment

Combination therapy — pairing pharmacotherapy with behavioral support — produces the highest quit rates. Varenicline (Chantix) has the strongest evidence. Nicotine replacement therapy (NRT) — particularly combining a patch with a short-acting form — and bupropion are effective alternatives. Behavioral counseling significantly improves outcomes regardless of which medication is used.

Nicotine is highly addictive — acting on the same dopamine reward pathways as other addictive substances. Physical withdrawal peaks within 2–3 days and substantially diminishes within 2–4 weeks. Psychological cravings triggered by situational cues (stress, social settings, alcohol) can persist for months and are the most common cause of relapse.

Yes — NRT is safe for most people, including those with cardiovascular disease. The nicotine delivered is significantly less harmful than the nicotine plus thousands of toxins in cigarette smoke. OTC formulations include the patch, gum, and lozenge. Prescription-strength inhaler and nasal spray provide faster delivery for those who benefit from more rapid relief.

Prior quit attempts are not failures — they are practice. Most people require multiple attempts before achieving sustained cessation. Each attempt provides information about triggers and strategies. Using evidence-based pharmacotherapy significantly improves success rates compared to willpower alone. A clinical consultation creates a structured, individualized quit plan.

Varenicline may cause nausea (improved by taking with food), vivid dreams, and rarely mood changes. Bupropion may cause insomnia and dry mouth and lowers seizure threshold. NRT formulations cause local effects — skin irritation (patch), hiccups or mouth soreness (gum, lozenge). All are considered very favorable compared to the risks of continued smoking.